Table 3.
Absolute mortality difference and observed change in left ventricular ejection fraction
| Classification | ‘Reduced’ LVEF |
‘Mid–range’ LVEF | ‘Preserved’ LVEF | |||
|---|---|---|---|---|---|---|
| LVEF at baseline | <20% | 20–25% | 26–34% | 35–39% | 40–49% | ≥50% |
| Sinus rhythm: all aetiologya | ||||||
| Change in absolute mortality; beta-blockers vs. placebo (95% CI)b | n = 2552 | n = 3885 | n = 5076 | n = 1929 | n = 575 | n = 244 |
| –6.9% (–10.3% to –3.5%) | –3.9% (–6.3% to –1.6%) | –3.2% (–5.1% to –1.4%) | –3.4% (–6.1% to –0.7%) | –5.2% (–10.0% to –0.3%) | ||
| +2.3% (–5.3% to + 9.9%) | ||||||
| Change in LVEF from baseline to follow-up; mean difference (SE) beta-blockers vs. placeboc | n = 1106 | n = 1068 | n = 1600 | n = 375 | n = 251 | n = 201 |
| +4.7% (0.5%) | +4.0% (0.5%) | +4.2% (0.5%) | +4.9% (0.9%) | +1.9% (1.1%) | +0.1% (1.2%) | |
| Atrial fibrillation: all aetiology | ||||||
| Change in absolute mortality; beta-blockers vs. placebo (95% CI)a | n = 494 | n = 867 | n = 1101 | n = 367 | n = 146 | n = 73 |
| +2.8% (–5.3% to + 10.9%) | –4.1% (–9.3% to + 1.1%) | –0.8% (–5.5% to + 3.9%) | –3.2% (–10.7% to + 4.3%) | +3.2% (–10.4% to + 16.7%) | +0.3% (–14.0% to + 14.6%) | |
| Change in LVEF from baseline to follow-up; mean difference (SE) beta-blockers vs. placebob | n = 177 | n = 200 | n = 369 | n = 98 | n = 93 | n = 59 |
| +4.6% (1.7%) | +3.4% (1.2%) | +1.5% (1.0%) | +0.1% (1.9%) | +4.8% (1.9%) | –2.2% (3.0%) | |
CI, confidence interval; LVEF, left ventricular ejection fraction; SE, standard error of the mean difference; IQR, interquartile range.
a
See Supplementary material online, Table S6 for data according to ischaemic/non-ischaemic aetiology in sinus rhythm.
b
Median follow-up of 1.3 years (IQR 0.8–1.9).
c
Median 1.0 years after baseline assessment (IQR 0.3–2.0).